Form 4: Intra-Cellular Therapies CEO Executes Stock Option and Sells Shares Under 10b5-1 Plan

Intra-Cellular Therapies' CEO, Sharon Mates, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Sharon Mates, CEO of Intra-Cellular Therapies, exercised stock options to acquire 102,697 shares of common stock at a price of $12.73 per share on December 4th and 5th, 2024.
• Concurrently, Ms. Mates sold a total of 102,697 shares of common stock on December 4th and 5th, 2024, at weighted average prices ranging from $84.0645 to $86.0048 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 3, 2024.
• Following these transactions, Ms. Mates beneficially owns 1,070,329 shares of Intra-Cellular Therapies common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions are part of a pre-planned strategy, which is normal for executives. However, the sale of shares could be perceived negatively by some investors.

Positives

• The stock options were exercised at a significantly lower price ($12.73) than the sale price, indicating a potential profit for the CEO.
• The sales were executed under a pre-arranged 10b5-1 plan, which is a common practice for insiders to avoid accusations of insider trading.

Negatives

• The sale of 102,697 shares by the CEO could be interpreted negatively by some investors, potentially signaling a lack of confidence in the company's future performance, although this is mitigated by the pre-planned nature of the sales.

Risks

• While the sales were under a 10b5-1 plan, large sales by insiders can sometimes create short-term downward pressure on the stock price.
• The market may react negatively to the CEO selling shares, even if it is part of a pre-planned strategy.

Industry Context

This type of transaction is common for executives of publicly traded companies, especially those with stock-based compensation. The use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Many executives at publicly traded companies use 10b5-1 trading plans to manage their stock sales.
• The exercise of stock options and subsequent sale of shares is a typical form of compensation for executives in the biotechnology industry.
• The price range of the sales is consistent with the current market price of ITCI stock.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sales, potentially causing short-term price fluctuations.
• The transactions do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

insider trading, stock options, share sales, Rule 10b5-1, beneficial ownership, Intra-Cellular Therapies, ITCI, CEO, Sharon Mates